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background: Patients with heart failure and preserved left ventricular ejection fraction (LVEF) have generally been considered to carry a better 
prognosis that those with reduced LVEF. Recent studies however, have challenged this postulate. We sought to determine if the use of N-Terminal 
Pro- B-Type Natriuretic Peptide (NT-ProBNP) as a biomarker could have a prognostic value in patients with preserved and reduced LVEF fraction 
hospitalized with acute decompensated heart failure (ADHF).
Method: We screened 620 patients with ADHF hospitalized at our institution, between June of 2010 and October of 2013, We measured NT-ProBNP 
concentration (RIA) and the LVEF by echocardiogram on admission. In hospital all cause mortality was evaluated according LVEF and NT-ProBNP 
values.
results: There were 190 patients with LVEF of 50% or more, 234 with LVEF between 35-49% and 196 had less than 34% of LVEF. In total, 86 
patients (13.8%) met the primary endpoint of all-cause mortality. Overall patient with preserved LVEF had lower mortality, however, the risk of death 
increased with higher levels of NT-ProBNP (see table).
conclusions: Mortality in patients with ADHF and preserved LVEF is not necessarily low and appears to depend on the levels NT-ProBNP at 
admission.
Mortality in group by LVEF according to NT-Pro-BNP Level
NT-Pro-BNP < 250
NT-Pro-BNP 251-
1000
NT-Pro-BNP 1001-
5000
NT-Pro-BNP 5001-
15000
NT-Pro-BNP 
>15001
Total P value
LVEF > 50% Deaths 0 (0%) 1 (3.3%) 4 (6.0%) 10 (18.9%) 6 (20.0%) 21 (11.06%) 0.003
LVEF 35-49% Deaths 0 (0%) 3 (9.4%) 4 (3.8%) 5 (8.5%) 7 (21.9%) 19 (8.06%) 0.017
LVEF <34% Death 1 (14.3%) 2 (22.2%) 8 (13.6%) 13 (21.3%) 22 (36.7%) 46 (23.46%) 0.010
